Knockdown of hypoxia-inducible factor-1 alpha reduces proliferation, induces apoptosis and attenuates the aggressive phenotype of retinoblastoma WERI-Rb-1 cells under hypoxic conditions

Annals of Clinical and Laboratory Science

Volumn 44, Issue 2, 2014, Pages 134-144

  Xia, Tian ^a   Cheng, Hao ^b   Zhu, Yu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

HIF 1 ; knockdown of HIF 1 ; Retinoblastoma; siRNA

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; BIRC5 PROTEIN, HUMAN; GLUCOSE TRANSPORTER 1; INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; SLC2A1 PROTEIN, HUMAN; VASCULOTROPIN A;

APOPTOSIS; ARTICLE; CELL HYPOXIA; CELL PROLIFERATION; PHENOTYPE; PRIORITY JOURNAL; RETINOBLASTOMA CELL LINE; CELL ADHESION; CELL CYCLE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; PATHOLOGY; RETINOBLASTOMA; TUMOR CELL LINE; TUMOR INVASION;

APOPTOSIS; CELL ADHESION; CELL CYCLE; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASM INVASIVENESS; PHENOTYPE; RETINOBLASTOMA; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899738474     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Abramson DH. Retinoblastoma incidence in the United States. Arch Ophthalmol 1990;108:1514.
2. Friedman DL, Himelstein B, Shields CL. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000;18:12-17.
3. Benz MS, Scott IU, Murray TG, Kramer D, Toledano S. Complications of systemic chemotherapy as treatment of retinoblastoma. Arch Ophthalmol 2000;118:577-578.
4. Beck MN, Balmer A, Dessing C, Pica A, Munier F. First-line chemotherapy with local treatment can prevent externalbeam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol 2000;18:2881-2887.
5. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
6. Chi JT, Wang Z, Nuyten DS, Rodrigez EH, Schaner ME. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006;3:370.
7. Toffoli S, Michiels C. Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. FEBS J 2008;275:2991-3002.
8. Wu XZ. New strategy of antiangiogenic therapy for hepatocellular carcinoma. Neoplasma 2008;55:472-81.
9. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor1 is a basic-helix-loop-helix-PAS heterodimerregulated by cellular O2 tension. Proc Natl Acad Sci USA 1995 Jun6;92(12):5510-4.
10. Semenza GL. Hypoxia-inducible factor-1: master regulator of O2 homeostasis. Curr Opin Genet Dev 1998;8:588-94.
11. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993;90:4304-4308.
12. Aebersold DM, Burri P, Beer KT. Expression of hypoxia-inducible factor- 1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61:2911-6.
13. Dellas K, Bache M, Pigorsch SU. Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer. Strahlenther Onkol 2008;184:169-74.
14. Griffiths EA, Pritchard SA, Valentine HR. Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer 2007;96:95-103.
15. Kappler M, Taubert H, Holzhausen HJ. Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-andneck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters. Strahlenther Onkol 2008;184:393-9.
16. Trastour C, Benizri E, Ettore F. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer 2007;120:1451-8.
17. Putra AC, Tanimoto K, Arifin M, Hiyama K. Hypoxiainducible factor-1α polymorphisms are associated with genetic aberrations in lung cancer. Respirology 2011 Jul;16(5):796-802.
18. Piña Y, Houston SK, Murray TG, Koru-Senqul T, Decatur C Scott WK, Nathanson L, Clarke J, Lampidis TJ. Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomicsexpression in LH(BETA)T(AG) retinal tumors. Clin Ophthalmol 2012;6:817-30.
19. Piña Y, Decatur C, Murray T, Houston S, Gologorsky D Cavalcante M, Cavalcante L, Hernandez E, Celdran M, Feuer W, Lampidis T. Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors. Clin Ophthalmol 2011;5:337-43.
20. Houston SK, Piña Y, Murray TG, Boutrid H, Cebulla C Schefler AC, Shi W, Celdran M, Feuer W, Merchan J, Lampidis TJ. Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH (BETA) T (AG) retinoblastoma tumors. Clin Ophthalmol 2011 Jan 27;5:129-37.
21. Wang XL, Niu YJ, Ma JM. HIF-1alpha, HPSE and VEGF promote malignant progression of retinoblastoma. Zhonghua Yan Ke Za Zhi 2010 Feb;46(2):140-4 Chinese.
22. Wu D, Yotnda P. Induction and testing of hypoxia in cell culture. J Vis Exp 2011 Aug;12(54).
23. Johnson M, Zaretskaya I, Raytselis Y, Merezhuk Y, McGinnis S, Madden TL. NCBI BLAST: a better web interface. Nucleic Acids Res 2008 Jul1;36(Web Server issue):W5-9.
24. Xia Y, Choi HK, Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 2012 Mar;49:24-40.
25. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732.
26. Li H, Ko HP, Whitlock JP. Induction of phosphoglycerate kinase 1 gene expression by hypoxia. Roles of Arnt and HIF-1alpha. J Biol Chem 1996;271:21262-21267.
27. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J Chen J, Niizeki H, Kawamura K, Hosokawa M, Asaka M. Constitutive expression of hypoxia-inducible factor-1 alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001;61:6548-54.
28. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R Richter E, Katschinski DM, Wenger RH. The hypoxia-inducible factor-1 is a negative factor for tumor therapy. Oncogene 2003;22:3213-20.
29. Vasishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, de Fougerolles T, Maraganore J. A status report on RNAi therapeutics. Silence 2010;8;1(1):14.
30. Hong SS, Lee HS, Kim KW. HIF-1a: a valid therapeutic target for tumor therapy. Cancer Res Treat 2004;36:343-353.
31. Lyons JM, 3rd, Schwimer JE, Anthony CT, Thomson JL CundiffJD, Casey DT, Maccini C, Kucera P, Wang YZ Boudreaux JP, Woltering EA. The role of VEGF pathways in human physiologic and pathologic angiogenesis. J Surg Res 2010;159(1):517-527.
32. Bell GI, Kayano T, Buse JB, Burant CF, Takeda J, Lin D Fukumoto H, Seino S. Molecular biology of mammalian glucose transporters. Diabetes Care 1990 May;13 (3):198-208.
33. Wu SF, Zhang JW, Qian WY, Yang YB, Liu Y, Dong Y, Zhang ZB, Zhu YP, Feng YJ. Altered expression of survivin, Fas and FasL contributed to cervical cancer development and metastasis. Eur Rev Med Pharmacol Sci 2012 Dec;16(15): 2044-50.
34. Nurwidya F, Takahashi F, Minakata K, Murakami A Takahashi K. From tumor hypoxia to cancer progression: the implications of hypoxia-inducible factor-1 expression in cancers. Anat Cell Biol 2012 Jun;45(2):73-8.
35. Yang L, Kang WK. The effect of HIF-1α siRNA on growth and chemosensitivity of Mia-paca cell line. Yonsei Med J 2008;49:295-300.
36. Sermeus A, Genin M, Maincent A, Fransolet M, Notte A Leclere L, Riquier H, Arnould T, Michiels C. Hypoxia-induced modulation of apoptosis and BCL-2 family proteins in different cancer cell types. PLoS One 2012;7(11):e47519.
37. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselman SK, Dewerchin. Role of HIF-1α in hypoxia-mediated apoptosis cell proliferation and tumour angiogenesis. Nature 1998;394:485-90.
38. HöpflG, Wenger RN, Ziegler U, Stallmach T, Gardell O Achermann R, Wergin M, Kaser-Hotz B, Saunders HM Williams KJ, Stratford IJ, Gassmann M, Desbaillets I. Rescue of hypoxia-inducible factor-1 alpha-deficient tumor growth by wild-type cells is independent of vascularendothelial growth factor. Cancer Res 2002;May15; 62 (10):2962-70.
39. Akundi RS, Rivkees SA. Hypoxia alters cell cycle regulatory protein expression and induces premature maturation of oligodendrocyte precursor cells. PLoS ONE 2009;4(3):e4739.
40. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. Stabilization of wild-type p53 by hypoxiainducible factor1. Nature 1998;392:405-8.
41. Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ Giacia AJ. Hypoxia induces accumulation of p53 protein, but activation of a G1 phase checkpoint by low oxygen conditions is independent of p53 status. Mol Cell Biol 1994;14:6264-77.
42. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004;57:1009-1014.
43. Loor G, Schumacker PT. Role of hypoxia-inducible factor in cell survival during myocardial ischemia-reperfusion. Cell Death Differ 2008;15:686-690.
44. Alvarez-Tejado M, Naranjo-Suàrez S, Jimènez C, Carrera AC Land'azuri MO, del Peso L. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells. J Biol Chem 2001;276:22368-74.
45. Hurst DR, Welch DR. Metastasis suppressor genes: At the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol 2011; 286: 107-180.
46. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011 October 14;147(2):257-292.
47. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 2010;70:5649-69.
48. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011;147:275-92.
49. Arif M, Iqbal Z, Zia-ul-Islam. Retinoblastoma presenting as metastasis. J Ayub Med Coll Abbottabad 2010; Jan-Mar;22(1):109-11.
50. Dunkel IJ, Aledo A, Kernan NA. Successful treatment of metastatic retinoblastoma. Cancer 2000;89:2117-2121.
51. Chen LL, Blumm N, Christakis NA, Barabási A-L, Deisboeck TS. Cancer metastasis networks and the prediction of progression patterns. Br J Cancer 2009 September1;101(5):749-758.
52. Pistollato F, Rampazzo E, Persano L, Abbadi S, Frasson C Denaro L, D'Avella D, Panchision DM, Della Puppa A, Scienza R, Basso G. Interaction of hypoxia inducible factor-1alpha and Notch signaling regulates medulloblastoma precursor proliferation and fate. Stem Cells 2010;28:1918-1929.
53. Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA, Jensen RL. Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res 2007,13:2441-2448.
54. Chen N, Chen X, Huang R, Zeng H, Gong J, Meng W, Lu Y Zhao F, Wang L, Zhou Q. BCL-xL is a target gene regulated by hypoxia-inducible factor-1 alpha. J Biol Chem 2009,284:10004-10012.
55. Dyer MA. Mouse models of childhood cancer of the nervous system. J Clin Pathol 2004 Jun;57(6):561-76.
56. Ernst W, Zimara N, Hanses F, Männel DN, Seelbach-Göbel B Wege AK. Humanized mice, a new model to study the influence of drug treatment on neonatal sepsis. Infect Immun 2013 May;81(5):1520-31.